Literature DB >> 6600615

The natural disease course of ankylosing spondylitis.

S Carette, D Graham, H Little, J Rubenstein, P Rosen.   

Abstract

One hundred fifty war veterans with ankylosing spondylitis were entered into a prospective study in 1947. In 1957, 142 were traced, and they have been reviewed periodically. Eighty-one of these patients were still alive in 1980. Information was obtained from 67 (83%) of the survivors and 51 were reexamined. This report is based on the clinical findings in these 51 patients, who have a mean disease duration of 38 years. Forty-seven (92%) were functioning well. The disease in 21 (41%) had progressed to cause severe spinal restriction. Of those, 12 had peripheral joint involvement early in their course and 9 had iritis. Seventy-four percent of the patients who had mild spinal restriction after 10 years did not progress to having more severe restriction. Eighty-one percent of the patients who had severe spinal restriction in 1980 were severely restricted within the first 10 years. Hips that were normal after 10 years of disease did not become diseased subsequently. This study suggests that a predictable pattern of ankylosing spondylitis emerges within the first 10 years of the disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6600615     DOI: 10.1002/art.1780260210

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  63 in total

1.  Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !?

Authors:  J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 2.  Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences.

Authors:  J Braun; J Xiang; J Brandt; H Maetzel; H Haibel; P Wu; S Kohler; M Rudwaleit; S Siegert; A Radbruch; A Thiel; J Sieper
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 3.  Ankylosing spondylitis: introductory comments on its diagnosis and treatment.

Authors:  M A Khan
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

4.  Dynamics of syndesmophyte growth in AS as measured by quantitative CT: heterogeneity within and among vertebral disc spaces.

Authors:  Sovira Tan; Jianhua Yao; John A Flynn; Lawrence Yao; Michael M Ward
Journal:  Rheumatology (Oxford)       Date:  2014-11-12       Impact factor: 7.580

5.  Established criteria for disease controlling drugs in ankylosing spondylitis.

Authors:  D D Gladman
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

6.  How to diagnose axial spondyloarthropathy early.

Authors:  N Barkham; H Marzo-Ortega; D McGonagle; P Emery
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

7.  Psoriatic spondyloarthropathy: a long term prospective study.

Authors:  J G Hanly; M L Russell; D D Gladman
Journal:  Ann Rheum Dis       Date:  1988-05       Impact factor: 19.103

8.  Unusual radiographic features in a female patient with ankylosing spondylitis.

Authors:  T J Cunningham; P M Cumber; G Evison; P J Maddison
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

9.  T-cell responses to versican in ankylosing spondylitis.

Authors:  Tae-Jong Kim; Tae-Hwan Kim; Hyun-Joo Lee; Bitnara Lee; A Robin Poole; Robert D Inman
Journal:  Rheumatol Int       Date:  2009-12-11       Impact factor: 2.631

Review 10.  Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.

Authors:  Nigel Armstrong; Manuela Joore; Thea van Asselt; Kate Misso; Nathan Manning; Florian Tomini; Jos Kleijnen; Rob Riemsma
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.